CAR-T Cancer Drugs Front And Center At ARM Investor Day
Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.
You may also be interested in...
The latest cancer drug development news and highlights from our FDA Performance Tracker.
Kite Pharma investors were spooked on May 8 when the company revealed that an extremely ill patient died from cerebral edema related to its lead CAR-T candidate – the same severe side effect that derailed Juno's competing cell therapy.
As companies like Novartis, bluebird bio and Kite Pharma press on with developing cancer treatments based on cutting edge CAR T-cell technology, the new chair of the European Medicines Agency’s Committee for Advanced Therapies, Martina Schüssler-Lenz, tells the Pink Sheet about plans to help makers of these and other innovative advanced therapies.